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Malnutrition in the acutely ill patient:  
is it more than just protein and energy?
Introduction
Malnutrition is common in acutely ill patients, occurring in 30-
50% of hospitalized patients.1-3 This prevalence may be higher in 
critically ill patients. Hospital malnutrition has been associated with 
an increased risk of complications, particularly in surgical patient.3,4 
Malnutrition in hospitalized patients also increases hospital costs5 
and is associated with increased long-term mortality.6 Unfortunately, 
patients’ nutritional status often becomes significantly more 
compromised during their ICU  stay, due to a number of factors, 
some intrinsic to the patient and some iatrogenic. Most troubling is 
data showing that more than half of all ICU patients worldwide are 
significantly underfed based on the energy they are prescribed to 
receive for the first two weeks of ICU care.7 In addition, to nutrition’s 
probable key role in survival in the ICU setting following an acute 
illness/injury, significant mortality occurs after critically ill patients are 
discharged from hospital. More than 50% of the 6-month mortality 
following severe sepsis occurs after the patient has been discharged 
from the ICU.8 Many of these deaths are believed to occur indirectly 
as a result of catabolism, loss of lean body mass, lack of therapeutic 
physical activity, and ultimately weakness and inability to walk.9,10 
These patients often go to rehabilitation centers or go home only to 
die of pulmonary embolus or pneumonia because they are unable 
to stand, get out of bed, or perform activities of daily life. Although 
these patients are seen as a “success” because they survived their 
acute illness and were discharged from the ICU, sadly, many of 
these patients ultimately die or have severely limited qualities of life. 
Thus, the aim of nutritional support should not only involve providing 
care for the acute phase of illness with vasopressors, resuscitation, 
ventilation, and antibiotics to enhance survival, but should also aim 
to, apart from minimizing the mandatory catabolism that occurs 
during the acute phase, manage the convalescent phase of severe 
illness when the key intervention becomes nutrition, anabolism, 
and rehabilitation. Finally, new data has indicate that malnutrition 
may not be limited to the traditionally believed protein and energy 
(macronutrient) deficits as recent evidence supports the concept 
that adequate nutrition may also hinge on our ability to provide 
key pharmacologically acting nutrients11 (such as glutamine and 
arginine). This data has helped spawn the new field of “nutritional 
pharmacology”. This review will cover the latest thinking in the field 
of malnutrition in the acutely ill patient.
Pathophysiology and teleology of malnutrition and 
nutrition therapy in acute illness
The last 50 years of medicine and critical care have brought great 
advances in the treatment of disease with novel pharmacologic 
agents. Largely ignored has been the vital role of basic nutrients and 
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energy in the treatment of critical illness and injury. This poor critical 
care nutrition delivery has resulted from years of poorly designed or 
non-generalizable trials in the fundamental feeding and nutritional 
support of our patients. Further, there has been a lack of laboratory-
based exploration into the mechanistic science underlying the risks 
and benefits of nutrition and nutrient administration following injury 
and illness. 
Traditionally, the lack of focus on nutrition as a vital supportive therapy 
in the critical care setting has been due to the observation that, in 
nature, acute illness reduces food intake by inducing anorexia, loss 
of appetite, or simply not permitting the organism to forage for food. 
At its discovery, tumor necrosis factor-alpha (TNF-α) was known as 
cachexin. This and other cytokines released in the first few hours 
following stress and injury induces anorexia and catabolism. The 
early systemic inflammatory response (SIRS) pathway has been 
preserved through many years of evolution. Thus, the body has 
previously utilized anorexia and catabolism in the face of stress and 
injury as a key survival mechanism. However, it must be realized that 
until the last 150 years if the proverbial “saber-tooth” tiger attacked, 
one had perhaps 48 hours to recover before one died. Even if one 
survived your initial injury, one was often left behind by one’s tribe 
as a liability, for one could not gather food, reproduce, and they 
likely had to carry the injured who was less than ideal when other 
“tigers” were lurking. Survival from acute injury involved achieving 
hemostasis and preventing rapid, overwhelming infection. Thus, 
eating and anabolism were not part of this primal fight for survival. 
Our understanding and management of this survival mechanism has 
changed dramatically since the evolution of emergency medicine, 
surgery, and critical care. In today’s environment severely ill and 
injured individuals are supported through massive injurious insults, 
when such are compatible with recovery. Thus, while we have 
learned to accept that lean body mass catabolism is mandatory, 
long-term survival mandates that we minimize lean body loss by 
early energy/substrate delivery in the acute phase. Aggressive 
feeding and perhaps pro-anabolic therapy should also follow such 
support in the recovery or convalescent phase. Indeed, adequate 
nutrition may hinge not only on how much energy we provide, 
but also on the ability to provide key pharmacologically acting 
nutrients.11 For example, rapid mobilization of amino acids stored 
in muscle is a vital mechanism for survival following acute illness 
or injury. These amino acids (such as arginine and glutamine) are 
utilized as obligate nutrient sources for the immune system and 
the gut. Recent data indicates that these amino acids also serve 
as a key stress signals that initiate activation of fundamental cell 
protective pathways following an insult.11 For various teleological 
reasons, the body becomes rapidly depleted of these substrates and 
their supplementation may be fundamental for optimal recovery. This 
data has helped spawn the new field of “nutritional pharmacology”. 
Epidemiology and role in outcome of ICU malnutrition
A recent review of the world literature found that in 20 studies 
since 1990 the mean malnutrition rate in the hospital was 41.7%.12 
Hospital malnutrition has been associated with an increased risk 
of complications, particularly in surgical patients.3,4 Malnutrition in 
hospitalized patients also increases hospital costs5 and is associated 
with increased long-term mortality.6 Unfortunately, patients’ 
nutritional status often becomes significantly more compromised 
during their ICU stay. This malnutrition is due to a number of factors, 
some intrinsic to the patient and some iatrogenic.  
The key to providing successful nutrition therapy appears to 
begin with the initiation of enteral or oral feeding within 24-48 
hours of admission to the ICU, and appropriate resuscitation. 
A recent observational cohort study of nutrition practices in 167 
ICUs across 21 countries was conducted to evaluate worldwide 
nutrition practices in 2 772 patients. Despite multiple international 
guidelines recommending early initiation of enteral nutrition in the 
ICU, success was achieved in terms of delivering approximately only 
50% of the prescribed daily energy for the entire first two weeks of 
ICU admission. In addition in some major developed countries, like 
the U.S, it takes over 60 hours to initiate any enteral feeding at all.7 
By comparison, the administration of only 500 mg of the prescribed 
1 gram of vancomycin to be given daily to a patient dying of MRSA 
sepsis would never be tolerated. Yet, inadequate delivery of energy 
and nutrients is a daily occurrence in every ICU in the world (except, 
perhaps ironically, in Burn Intensive Care Units, where often the most 
severely injured patients in the hospital reside). 
As with any pharmacologic therapy, it appears that not all ICU patients 
are created equal when it comes to their need for energy and protein. 
In the same cohort study,7 body mass index (BMI, kg/m2) was utilized 
as a surrogate marker of nutritional status prior to ICU admission.13 
Regression models were developed to explore the relationship 
between the nutrition support received during hopsitalisation and 
the 60-day mortality in relation to BMI status. Overall, study patients 
received a mean of 1 034 kcal/day and 47 g protein/day for the first 
14 days. There was a significant inverse linear relationship between 
the odds of mortality and total daily energy received.13 An increase 
of 1 000 calories per day was associated with an overall reduction 
in mortality (odds ratio for 60-day mortality 0.76, 95% confidence 
intervals [CI] 0.61-0.95, p=0.014). This beneficial treatment effect 
of increased energy provision on mortality was observed in patients 
with a BMI < 25 and > 35 with no benefit for patients in the BMI 
25 to < 35 group. Mortality was also reduced for every additional 
30 g of protein per day given to these patients. This mortality benefit 
held true after adjusting for the severity of illness and other related 
patient factors. Thus, like with all pharmacologic interventions, some 
patients may benefit a great deal more from the provision of energy 
early in their ICU stay, while others may not benefit at all. This is 
a key issue, when considering the use of early parenteral nutrition 
(PN) whether as a primary energy source or more appropriately as 
a supplement to the often inadequate enteral feeding support. From 
this data, it might be inferred that early use of PN might be of benefit 
in patients with a BMI of < 25 or > 35, whereas a patient with a BMI 
of 25-35 may not benefit from early PN use, and in fact may only be 
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exposed to the inherent risks that PN can carry. A number of large 
randomized controlled trials (RCTs) are now planned or underway to 
investigate this relationship further. 
Does nutrition play a role in long-term outcome and 
quality of life? 
In addition to nutrition’s probable key role in survival in the ICU 
setting following an acute illness/injury, significant mortality occurs 
after critically ill patients are discharged from the hospital. More than 
50% of the six-month mortality following severe sepsis occurs after 
the patient has been discharged from the ICU.8 Recent data reveal 
that one third of patients discharged following community acquired 
pneumonia are dead at one year.9 It should therefore always be born 
in mind that nutritional support is necessary in the convalescent 
phase of severe illness when the key intervention becomes nutrition, 
anabolism, and rehabilitation. 
Nutritional management of the ICU and acutely ill ICU 
patient 
Key considerations in the nutritional therapy of ICU patient include: 
(1) route of feeding: enteral versus parenteral, (2) when to feed: 
begin within 24-48 hours of ICU admission preferred (early enteral 
feeding), and (3) what to feed: a standard enteral formula or one with 
targeted functional pharmaconutrients. 
Practice guidelines in Europe, Canada, and the US endorse enteral 
feeding for patients who are critically ill and haemodynamically 
stable.14-16 Enteral nutrition is preferred over parenteral nutrition 
(PN) for most ICU patients—an evidence-based practice supported 
by a number of clinical trials involving a variety of critically ill 
patient populations, including those with trauma, burns, head injury, 
major surgery, and acute pancreatitis.16,17 For ICU patients who are 
haemodynamically stable and have a functioning gastrointestinal 
tract (GI) tract, early enteral feeding (within 24-48 hours of arrival in 
the ICU) has become a recommended standard of care.14-16 Experts 
identify these early hours as a window of opportunity to provide 
nutrition that maintains gut barrier function and support immune 
responses.14,16 
Patients with extreme haemodynamic instability (rising plasma/
blood/serum lactate concentrations or escalating requirements for 
vasopressors) are generally not considered as candidates for enteral 
feeding. However, early findings suggest the use of early enteral 
feeding in other vasopressor-dependent patients may be possible. 
In one study, vasopressor-dependent patients who were given 
enteral feeding within the first 48 hours had a significant survival 
advantage compared to those whose feeding was delayed; in fact, 
the sickest patients (on multiple vasopressors) experienced the 
greatest benefit.18 It should be noted, however, that this finding is 
based on an observational study only and confirmatory prospective 
from controlled studies is warranted.
PN is necessary in critically ill patients who do not have an intact 
GI tract or who cannot meet goal energy targets via the enteral 
route, but current guidelines do not agree on when to initiate PN.19 
For patients who are intolerant or have other contraindications to 
enteral feeding, European guidelines recommend starting PN within 
24-48 hours, if the patient is not expected to be on oral nutrition within 
3 days.20 US guidelines hesitate to recommend PN on admission to 
the ICU; standard care (intravenous fluids) is recommended first, with 
PN reserved and initiated only after seven days in well-nourished 
patient.16 Both the ESPEN and ASPEN guidelines recommend early 
PN use (within 24 hours of ICU admission) in patients who are 
malnourished.16,20 Canadian guidelines state that PN should not be 
used in patients with an intact GI tract.21 
When enteral feeding alone is inadequate, some experts suggest 
the combined use of PN and enteral nutrition to meet energy and 
protein targets.13,19,22,23 Combination regimens are justified by 
observations that actual enteral intake typically meets only half of 
prescribed energy in ICU patients.24-27 For patients who are expected 
to be mechanically ventilated more than 72 hours and have body 
mass index (BMI) scores < 25 or > 35, each additional 1 000 kcal/
day or 30 g protein/day was reported to be associated with reduced 
mortality.13 However, clinical evidence for combination feeding 
remains unclear. In this regard, Casaer et al conducted a large, 
single center prospective, randomized trial (EPaNIC trial)28 comparing 
outcomes in critically ill patients on enteral nutrition who had early 
versus late initiation of PN (early: < 48 hours after ICU admission, 
n=2 312; late: day 8 or later after ICU admission; n=2 328). Results 
revealed patients on late-initiation PN had a relative increase of 6% 
in the likelihood of being discharged alive earlier from the ICU and 
from the hospital (P=0.04). Those in the late-initiation group also 
had significantly fewer ICU infections, shorter duration of mechanical 
ventilation and a shorter course of renal replacement therapy. 
Several aspects of the study limit generalizability of the findings to 
all ICU populations: (1) Patients with chronic malnutrition were not 
included in the study. (2) Patients in the trial received a low protein 
delivery (median of 0.8 g/kg/day protein (after day 3) for the study 
period in the early PN group. This protein target was below what is 
recommended by most guidelines for critically ill patients (typical 
recommendation: 1.3-1.5 g/kg/day (ESPEN guidelines). (3) Finally, 
the trial examined a low mortality-risk patient group with an average 
ICU mortality of 6.2% (90d mortality-11.2%) and a relatively low 
acuity patient group with an ICU LOS of 3.5 days, and mechanical 
ventilation period of two days. Accounting for the aforementioned 
limitations, The EPaNIC trial is unquestionably a key contribution 
to the literature on supplemental PN use in critical care. It would 
thus appear that the key conclusion of the EPaNIC trial is that in 
low mortality risk, non-chronically malnourished patients, early 
aggressive energy delivery via PN does not appear to be beneficial. In 
contrast, the recently published, single center TICACOS trial showed 
that hospital and 60-day mortality was reduced (p < 0.02 for both 
time points) in a higher mortality-risk group of ICU patients receiving 
additional energy via enteral nutrition supplemented with PN.29 In 
comparison to the EPaNIC trial, the TICACOS trial was conducted in 
a higher mortality-risk ICU patient group with an ICU mortality of 
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25.4% (60-day mortality 47%), ICU LOS of 12 days, and a mechanical 
ventilation period of 10.75 days. Thus, it is possible that in high 
mortality risk ICU patients supplemental PN may improve outcome. 
Additional trials on the use of enteral nutrition with supplemental PN 
have recently been completed or are underway. These forthcoming 
results should continue to clarify the utility of supplemental PN use 
in the ICU. 
Expert guidelines and mechanistic explanation for 
pharmaconutrition in the ICU/acutely ill patient
Evidence-based nutrition guidelines for critically ill patients have 
been developed in North America and Europe.15,16,21 While the 
guidelines agree in principle regarding pharmaconutrients, there are 
some differences in specific recommendations (Table I). 
Immune-modulating enteral nutrients: arginine 
There are a number of “conditionally essential” pharmconutrients, 
which become depleted during stress associated with surgery, 
trauma, and critical illness. These nutrients, are vital to maintenance 
of immune homeostasis as immune dysfunction is common in 
patients with nutritional deficits, particularly in patients following 
physical injury, such as trauma or surgical injury.30 A key example of 
this nutrient-induced immune dysfunction is the arginine deficiency 
known to develop in patients who have experienced surgery or 
trauma,30 as well as in malignancy settings.31 
Results of recent investigations have helped elucidate how the 
function of the immune system is intimately linked to arginine 
metabolism.31 Arginine has long been known as a biosynthetic 
substrate for nitric oxide (a signaling molecule for immune and 
other cells).32-34 However, the improved understanding of the 
pathophysiology following physical injury indicated that immature 
cells of myeloid origin appear in circulation and in lymph tissues. 
These cells express arginase-1, a key enzyme in the degradation of 
arginine. Coupled with poor arginine intake and with an inadequate 
endogenous synthesis of arginine, arginase 1 expression leads to 
a state of conditional arginine deficiency. The latter is associated 
with suppression of T-lymphocyte function; the cells sunthesising 
arginase-1 are thus called myeloid-derived suppressor cells 
(MDSC). Dysfunction of T-lymphocytes after surgery or trauma 
is characterized by a decrease in the number of circulating CD4 
cells; blunted T-cell proliferation; production of IL-2 and interferon 
gamma; and loss of the zeta (ζ) chain, a peptide essential in the 
T-cell receptor complex.31
Results of several clinical studies showed that repletion of arginine, 
along with Omega-3 (ω-3) fatty acids, helps restore T-lymphocyte 
numbers and function, i.e. CD4 cell counts and IL-2 production.31,35 
It also appears that dietary ω-3 fatty acids blunt the expression of 
arginase 1.36 Thus, substantial, but variable, evidence supports the 
concept that immune-modulating diets may exert their beneficial 
effects by restoring T-cell function that was impaired by MDSC-
mediated arginine depletion.
The clinical outcome data (more than 30 trials and nearly 3 000 
patients) support a significant treatment effect of arginine therapy 
(at doses delivered in immune-modulating nutritional formulas, 
~ 12 g/day) following major surgery; arginine treatment reduced risk 
of infection (relative risk, RR = 0.58; 95% confidence interval, CI, of 
0.48 to 0.69, P < 0.00001) and overall length of stay (LOS; weighted 
mean difference = -2.09 with 95% CI of -3.20 to -0.97, P = 0.0002) 
versus standard enteral nutrition37 please clarify what the stars refer 
to. However, very little benefit, and perhaps harm, is observed in 
septic patients.38,39 This potential harm may be caused by promotion 
of excessive nitric oxide production in patients with sepsis, in turn 
worsening SIRS and increasing risk for mortality.40
Table I: Summary of expert recommendations for specific pharmaconutrients in ICU/acutely ill patients15,16,21
Patients Canadian CPG* ESPEN* ASPEN/SCCM*
General ICU Arginine (no benefit)
Glutamine (intravenous: strong benefit)
No recommendation
Glutamine (intravenous: strong benefit)
Arginine (possible benefit)
Glutamine (enteral: possible benefit; 
intravenous: strong benefit)
Elective surgery No recommendation Arginine (benefit) Arginine (benefit)












Sepsis Arginine (harm) Arginine (harm if severe sepsis; benefit if 
mild)
Arginine (harm if severe sepsis; benefit if 
mild/moderate)
ALI/ARDS Ω-3 fatty acids and ω-6 gamma-linolenic 
acid (benefit)




Whole-protein formulas for most patients; 
hydrolyzed protein formula may be 
considered for patients with GI dysfunction 
such as short bowel syndrome, pancreatitis
Whole-protein formulas for most patients; 
hydrolyzed protein formula may be 
considered for GI dysfunction such as 
pancreatitis
Hydrolyzed protein formula may be 
considered for patients with GI dysfunction 
such as persistent diarrhea, pancreatitis
Abbreviations: Canadian Critical Care Practice Guidelines, Canadian CPG; European Society for Clinical Nutrition and Metabolism, ESPEN; American Society for Parenteral and Enteral Nutrition, ASPEN; Society of 
Critical Care Medicine, SCCM. 
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In summary, in the perioperative period formulations with arginine 
(commonly combined with ω-3 fatty acids in most trials) are given a 
grade A recommendation to reduce infection and shorten length of 
stay as compared to standard formulation. In fact, given the availble 
evidence from clinical trials with a consistent outcome of reduced 
infection, most experts would advocate arginine therapy in the peri-
operative period should be standard of care in high risk surgical 
patients.37 However, given that < 1% of surgical patients in the 
U.S. receive arginine therapy in the peri-operative period (personal 
communication, J. Ochoa M.D.), it is likely that a large, multi-center, 
definitive U.S. trial will be required to establish this practice. Trauma 
patients, may also benefit from supplemental arginine following 
injury.32 For patients with severe sepsis, arginine-supplemented 
enteral formulas should be used with extreme caution16 or avoided 
due to potential for harm.15,21,40,41This conservative approach supports 
the basic pharmacologic premise that with pharmaconutrients, 
as with traditional “drugs”, “one size does not fit all” and a given 
pharmaconutrient will benefit one patient and have no effect or risk 
in another.
Anti-inflammatory nutrients: omega-3 (ω-3) fatty acids
The systemic inflammatory response syndrome (SIRS) is a common 
sequelae of surgical and critical illness. Patients with SIRS can 
evolve to the more sever conditions such as: sepsis, acute lung injury 
(ALI), or acute respiratory distress syndrome (ARDS). An example of 
a widely studied anti-inflammatory pharmaconutrient is dietary ω-3 
fatty acids, which can blunt out-of-control inflammatory responses 
and improve outcome by modulating synthesis of pro- and anti-
inflammatory mediators.33,34,42
Dietary intake of certain fats, such as ω-3 Fatty Acids (found 
commonly in fish oil), can alter the fatty acid composition in 
membranes of cells involved in immune inflammatory responses, 
i.e. neutrophils and macrophages. Certain membrane fatty acids, 
e.g. arachidonic acid (AA) serve as precursors to inflammatory 
eicosanoid and leukotriene mediators, while other fatty acids 
(eicosapentaenoic acid (EPA); docosohexaenoic acid (DHA); gamma 
linolenic acid (GLA) are metabolized to form less pro-inflammatory 
mediators.33,34,42 The anti-inflammatory actions of ω-3 fatty acids 
EPA and DHA are thought to occur by: (1) blunting production of 
pro-inflammatory mediators as a result of substituting for AA in 
macrophage and neutrophil membranes and (2) inhibiting production 
of pro-inflammatory mediators from AA by competing for the 
metabolic enzymes cyclooxygenase and lipoxygenase. In addition, 
DHA and EPA are precursors of resolvins and protectins, which help 
resolve inflammation and reduce tissue injury.43
A recent review discusses the variability in outcome benefit seen 
in recent results of clinical trials utilizing ω-3 fatty acid therapy 
in critically ill patients.44 This variability is thought to be due to 
use in these trials of different formulations, doses, and type of 
administration (continuous versus bolus).44 However, studies 
examining the continuous administration of high dose (> 5 g/day) 
enteral ω-3 fatty acids (EPA) and borage oil (GLA) have consistently 
showed significant benefits in 3 clinical trials of mechanically 
ventilated patients with ALI/ARDS or sepsis/septic shock.45-47 Use 
of this anti-inflammatory therapy significantly reduced time on 
ventilator, ICU and LOS, and incidence of new organ failure. Further, 
in a meta-analysis of the data from these three studies showed that 
use of an ω-3 fatty acid therapy significantly reduced the risk of 
28-day mortality by 49%.48 Results of another large meta-analysis 
showed that ω-3 fatty acid therapy significantly reduced by half 
the risk for mortality and secondary infections and significantly 
shortened LOS by more than 6 days in ICU patients with sepsis/
ARDS.41 All guidelines currently recommend the use of continuously 
administered enteral ω-3 fatty acids in ALI/ARDS patients. Additional 
trials are being completed studying the effects of ω-3 fatty acids in 
early sepsis and further phase 2 dosing trials are needed to define 
the ideal dose and route and type of administration in ICU patients.44 
In summary, given the latest data, ω-3 fatty acid based formulas 
should be Recommended to be given as continuous enteral infusion 
with complete enteral feeding in ARDS patients. These formulas do 
not appear to be efficacious in patients, when given as a single agent 
and/or as bolus doses. 
Cell protective pharmaconutrients: glutamine
Both glutamine (GLN) and antioxidants have been found to play 
key roles in protecting cells against injury and patients against 
complications, such as infection, and mortality in the surgical, 
trauma, and critical care settings.21,33 In the interest of brevity only 
GLN will be discussed in this review. Other reviews on antioxidants 
in acute care settings provide additional additional information.33,49
GLN rapidly becomes deficient in many hospitalized patients, 
including those with sepsis, trauma, surgery, or burns.33,34,50,51 GLN 
is the most abundant free amino acid in the body, but stores are 
rapidly depleted during critical illness or injury.34,50,52 GLN serves as 
a metabolic substrate for enterocytes and immune cells, supporting 
barrier and immune functions.52 Recently, GLN has been proposed as 
a signaling molecule that is important in states of illness and injury, 
i.e. a messenger to turn on genes involved in cell protection and 
immune regulation.53 An example of this fundamental stress signaling 
function is GLN’s keys role in enhancing the synthesis of heat shock 
proteins (HSPs), which are essential to cellular recovery following 
injury and to protection against organ failure.52 In fact, GLN is proving 
to be required for the activation of the gene(s) for HSP expression, 
and GLN deficiency creates a state in which the transcription factor 
for the HSP genes [heat shock factor-1 (HSF-1)] cannot become 
activated and bind the promoter (heat shock element) for the HSP 
genes.54 This signal appears to be propagated via GLN’s metabolism 
in the O-GlcNAc pathway, which is a key pathway in the cell’s rapid 
response to stress and injury.55 Thus, GLN appears to be required for 
the cell to mount an appropriate response to stress or injury. 
GLN has shown the greatest clinical benefit in critically ill patients, 
who typically have the most severe GLN deficiency.56 Further, GLN 
Review Article: Malnutrition in the acutely ill patient: is it more than just protein and energy?
S6
Review Article: Malnutrition in the acutely ill patient: is it more than just protein and energy?
2011;24(3) SupplementS Afr J Clin Nutr
deficiency on admission to the ICU is correlated with increased 
mortality.57 The most recent data strongly support the use of GLN 
therapy to reduce mortality in patients receiving parenteral nutrition 
in the ICU.21 This recommendation is supported by all available 
clinical nutrition guidelines worldwide.15,16,21 Supporting data come 
from 4 level 1 and 13 level 2 RCTs totaling the experience of the 
nearly 900 patients studied; these studies reveal GLN-supplemented 
parental nutrition is associated with a significant reduction in overall 
mortality (RR 0.71 with 95% CI from 0.55 to 0.92, P = 0.008),21 
significant reductions in infection and LOS with parenteral GLN 
therapy.21 A meta-analysis of all GLN RCTs (both enteral and 
parenteral) indicate a statistically significant reduction in mortality 
in ICU patients of all types (21 studies, > 1 500 patients).21 As is 
true with any “drug”, adequate GLN dosing is essential for clinical 
benefit. A parenteral GLN dose of 0.5 gr/kg/day appears to be 
optimal for the survival benefits seen in previous trials. Further, an 
enteral GLN dose greater than 0.3 g/kg/day is required for benefit; 
0.5 g/kg/day (in divided portions) is likely optimal.21 Doses less than 
0.2-0.3 g/kg/day have typically not been associated with clinical 
benefit. While GLN supplementation is strongly recommended for 
the mortality reduction in patients receiving parenteral nutrition in 
the ICU (Grade A recommendation by all available guidelines), GLN 
supplemented enteral formulae are recommended (Grade B) only 
in burns and trauma patients.15,16,21 Moreover, guidelines generally 
support the enrichment with antioxidant vitamins and trace elements 
in all enteral formulas.15,16,21
In summary, the best practice approach for the treatment and 
prevention of malnutrition in the acutely ill patient includes (Table 
II) nutritional support delivery that should be initiated early in the 
patient care (< 24-48 hours post-surgery or ICU admit), preferentially 
via the enteral route. This should be supplemented by parenteral 
nutrition in “at risk” patients when adequate enteral energy cannot 
be provided. Pharmaconutrients to target therapy to specific disease 
states as separate components, much like an antibiotic or drug is 
given, should also be considered in the appropriate setting. 
The “renaissance” in our understanding of malnutrition and 
nutritional pharmacology is highlighted by a significant number of 
newly completed or ongoing RCTs (often multi-center) examining 
the benefits of nutrition therapy and pharmaconutrition. Further, 
mechanistic laboratory advances in our understanding of the role 
of nutrients as pharmacologic agents are now being translated into 
focused trials on specific nutrients. As such, it is exciting to see the 
application of basic clinical pharmacology, molecular biology, and 
clinical research principles to the better study of nutritional support 
in surgery and critical illness. The outcomes of these trial provide 
findings that afford better perspective on the questions around how 
to administer the right nutrients, in the right amounts, at the right 
time, safely. 
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